(0.91%) 5 064.20 points
(0.85%) 38 226 points
(1.51%) 15 841 points
(-0.05%) $78.96
(5.28%) $2.03
(0.07%) $2 312.70
(0.46%) $26.87
(0.77%) $962.25
(-0.09%) $0.932
(-0.35%) $10.99
(-0.10%) $0.798
(-1.36%) $92.00
@ $11.34
发出时间: 14 Feb 2024 @ 04:41
回报率: -6.17%
上一信号: Feb 13 - 04:34
上一信号:
回报率: -3.57 %
Live Chart Being Loaded With Signals
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation...
Stats | |
---|---|
今日成交量 | 192 947 |
平均成交量 | 478 022 |
市值 | 376.26M |
EPS | $0 ( 2024-03-28 ) |
下一个收益日期 | ( $-0.250 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -14.19 |
ATR14 | $0.00900 (0.08%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-25 | Opaleye Management Inc. | Buy | 20 000 | Common Stock, par value $0.001 per share |
2024-04-24 | Opaleye Management Inc. | Buy | 8 285 | Common Stock, par value $0.001 per share |
2024-04-23 | Opaleye Management Inc. | Buy | 11 715 | Common Stock, par value $0.001 per share |
2024-04-19 | Opaleye Management Inc. | Buy | 29 400 | Common Stock, par value $0.001 per share |
2024-03-28 | Opaleye Management Inc. | Buy | 50 000 | Common Stock, par value $0.001 per share |
INSIDER POWER |
---|
13.42 |
Last 96 transactions |
Buy: 4 652 789 | Sell: 3 289 598 |
音量 相关性
Harrow Health Inc 相关性 - 货币/商品
Harrow Health Inc 财务报表
Annual | 2023 |
营收: | $130.19M |
毛利润: | $90.55M (69.55 %) |
EPS: | $-0.750 |
FY | 2023 |
营收: | $130.19M |
毛利润: | $90.55M (69.55 %) |
EPS: | $-0.750 |
FY | 2022 |
营收: | $88.60M |
毛利润: | $63.21M (71.35 %) |
EPS: | $-0.510 |
FY | 2021 |
营收: | $72.48M |
毛利润: | $54.26M (74.87 %) |
EPS: | $-0.690 |
Financial Reports:
No articles found.
Harrow Health Inc
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。